According to our analysis, survival was longer for the lower G0S2 expression group than for the higher G0S2 expression group among the patients with WHO grade II–IV gliomas and WHO grade II/III gliomas in the TCGA dataset. This evidence concerns the gene G0S2 and central nervous system cancer.